Befovacimab (Anti-TFPI)
Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in haemophilia A/B research. MW: 143.24 kD.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | A2779 |
| Sku # | A2779-1mg*5 |
| Pricing | 1mg*5, $1690.00 |